Literature DB >> 16954603

Lack of association of HIV-1 biological or molecular properties with neurotropism for brain cells.

Susana Alvarez1, José Luis Jiménez, M Jesús Serramía, Milagros González, Carmen Cantó-Nogués, M Angeles Muñoz-Fernández.   

Abstract

Despite HAART, a significant number of HIV-1-infected patients develop neurological complications. However, the presence of specific neurotropic HIV-1 strains, the extent of viral replication in the brain, and the type of cells infected remain controversial issues. To address this controversy we have analyzed different V3 loop sequences of viral isolates from four vertically HIV-1-infected children who developed HIV-1-related encephalopathy. Moreover, we have determined that some biological and molecular properties of HIV-1 might contribute to AIDS neurological dysfunctions. We detected very different HIV-1 isolates (X4 and R5) in the brain despite no great differences in clinical, pathological, or immunological parameters. In vitro, no differences in replicative competence in glial or neuroblastoma cells were observed between virus isolated from the blood of children with or without clinical neurological symptoms. The expression of both CXCR4 and CCR5 RNAs was observed in the brain independently of HIV-1 infection and viral strain predominant in this location. Our results failed to show a particular phenotypic property of the HIV-1 virus that might explain its neurovirulence and/or neurotropism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954603     DOI: 10.1385/JMN:29:2:131

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   2.866


  61 in total

Review 1.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Authors:  T Pierson; J McArthur; R F Siliciano
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART).

Authors:  M Maschke; O Kastrup; S Esser; B Ross; U Hengge; A Hufnagel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

3.  Variable progression of HIV-associated dementia.

Authors:  F H Bouwman; R L Skolasky; D Hes; O A Selnes; J D Glass; T E Nance-Sproson; W Royal; G J Dal Pan; J C McArthur
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

4.  Ultrastructural localization of the RNA of immunodeficiency viruses using electron microscopy in situ hybridization and in vitroinfected lymphocytes.

Authors:  C Cantó-Nogués; D Hockley; C Grief; S Ranjbar; J Bootman; N Almond; I Herrera
Journal:  Micron       Date:  2001-08       Impact factor: 2.251

5.  Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection.

Authors:  M A Muñoz-Fernández; E Obregón; J Navarro; C Börner; M D Gurbindo; T H Sampelayo; E Fernández-Cruz
Journal:  Pediatr Res       Date:  1996-10       Impact factor: 3.756

Review 6.  Human immunodeficiency virus (HIV)-induced disease of the central nervous system: pathology and implications for pathogenesis.

Authors:  H Budka
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

7.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

Authors:  G Simmons; P R Clapham; L Picard; R E Offord; M M Rosenkilde; T W Schwartz; R Buser; T N Wells; A E Proudfoot
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

8.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  HIV-1 infection of primary human neuroblasts.

Authors:  F Ensoli; A Cafaro; V Fiorelli; B Vannelli; B Ensoli; C J Thiele
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  1 in total

1.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.